Skip to content

Comparative Evaluation of salivary LDH and CRP in patients

Comparative Evaluation of salivary LDH and CRP in patients with oral erosive lichenoid reaction before and after systemic corticosteroid therapy

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160126026209N2
Enrollment
40
Registered
2022-06-12
Start date
2022-05-22
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erosive lichen planus. Other lichen planus

Interventions

Intervention group: the patient will be given a dose of 0.5 to 1 mg per kg prednisolone daily for seven days followed by a reduction of 5 mg each subsequent day..

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Suffering from oral erosive lichenoid reaction that has been definitely diagnosed by histopathologic diagnosis The patient has consent to participate in the study

Exclusion criteria

Exclusion criteria: Presence of systemic and inflammatory disease (e.g. Covid disease, blood system malignancies, etc.) that affects study factors (LDH, CRP) The patient had been receiving former treatment for the study lesion Presence of another lesion in the patient's mouth

Design outcomes

Primary

MeasureTime frame
The measure of salivary lactate dehydrogenase. Timepoint: measurement of lactate dehydrogenase just before the beginning of systemic treatment and 14 and 28 days after beginning the use of systemic corticosteroid. Method of measurement: Non-stimulating saliva sampling.;The measure of salivary C Reactive Protein. Timepoint: measurement of C Reactive Protein just before the beginning of systemic treatment and 14 and 28 days after beginning the use of systemic corticosteroid. Method of measurement: Non-stimulating saliva sampling.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Saberi

Esfahan University of Medical Sciences

zahra.saberi@dnt.mui.ac.ir+98 31 3792 5514

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026